Normal tissue toxicity to the gastrointestinal (Gl) tract occurs frequently with chemoradiotherapy and represents a major clinical challenge. Unfortunately, no effective treatments exist to combat this significant clinical problem. The luminal epithelia of the Gl tract exist in physiologic hypoxia, and thus hypoxic signaling is crucial to the their survival and normal functions. Hypoxia-inducible factor-1 (HlF-1) is a transcription factor at the heart of the cellular hypoxia response whose levels fluctuate inversely with cellular oxygen tension. Stabilized HIF-1 expression has been shown to be critical for normal intestinal homeostasis as well as survival during inflammatory challenges. HIF-1 is required to maintain several basic functions of the intestine, such as barrier and absorptive functions. Augmenting HIF-1 expression in the intestine improves epithelial barrier functions, increases nutrient absorption and reduces apoptosis in response to infection and inflammatory stress. Conversely, intestinal specific knockouts of HIF-1 cause increased epithelial apoptosis in murine models of colitis. The oxygen dependent regulation of HIF is chiefly mediated through the prolyl hydroxylase domain (PHD)-containing proteins which hydroxylate proline moieties on HIF, and serve as a recognition site for the von Hippel Lindau (VHL) protein, which targets HIF for proteasomal destruction. To date, three oxygen-dependent prolyl hydroxylases have been identified (PHD1-3), however, the roles of each isoform in intestinal homeostasis is not clear. Because PHD proteins regulate HIF levels, and HIF, in turn protects the gut from inflammatory stress, it is our hypothesis that the PHD proteins regulates radiosensitivity in the gastrointestinal tract, such that deletion of specific PHD isoforms will afford radioprotection of the gut through HIF-medlated effects on epithelial integrity and crypt regeneration. In this proposal, we will: 1) investigate the specific contributions of PHD 1-3 on radioprotecting the Gl tract from hypofractionated and fractionated radiation with Project 2 and Core B, 2) determine the mechanisms of radioprotection by PHD inhibition with Project 3;3) explore the role of PHD 1-3 in the radiation response ofthe intestinal stem cell with Project 2, 4) determine the efficacy of a small molecule PHD inhibitor to protect the Gl tract with Project 2;and 5) determine the therapeutic efficacy of PHD 1-3 knockouts and small molecule inhibitors of PHD activity on tumor growth in response to radiation relative to normal tissue radioprotection with Project 4. This project represents a new paradigm change in the development of radioprotectors in that we are investigating the physiological basis of tissue radioprotection through alterations in epithelial barrier function.

Public Health Relevance

Gastrointestinal (Gl) toxicity is one of the most common and distressing acute side effects of systemic chemotherapy or abdominopelvic radiation therapy. For instance, nearly 75% of patients receiving pelvic radiotherapy experience acute radiation proctopathy, which often involves diarrhea and cramping. The sensitivity of the normal cells in the Gl tract limits dose escalation of radiotherapy to tumors in the abdomen or pelvis, and thereby hinder tumor eradication. Therefore, the need exists for a Gl tract radioprotector.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA067166-17
Application #
8744820
Study Section
Special Emphasis Panel (ZCA1-RPRB-2)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
17
Fiscal Year
2014
Total Cost
$746,922
Indirect Cost
$550,965
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Yuan, William; Jiang, Dadi; Nambiar, Dhanya K et al. (2017) Chemical Space Mimicry for Drug Discovery. J Chem Inf Model 57:875-882
Kariolis, Mihalis S; Miao, Yu Rebecca; Diep, Anh et al. (2017) Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies. J Clin Invest 127:183-198
Castellini, Laura; Moon, Eui Jung; Razorenova, Olga V et al. (2017) KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage. Nucleic Acids Res 45:3674-3692
VandeKopple, Matthew J; Wu, Jinghai; Baer, Lisa A et al. (2017) Stress-responsive HILPDA is necessary for thermoregulation during fasting. J Endocrinol 235:27-38
Aguilera, Todd A; Giaccia, Amato J (2017) Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase. Clin Cancer Res 23:2928-2933
Bobko, Andrey A; Evans, Jason; Denko, Nicholas C et al. (2017) Concurrent Longitudinal EPR Monitoring of Tissue Oxygenation, Acidosis, and Reducing Capacity in Mouse Xenograft Tumor Models. Cell Biochem Biophys 75:247-253
Vilalta, Marta; Hughes, Nicholas P; Von Eyben, Rie et al. (2017) Patterns of Vasculature in Mouse Models of Lung Cancer Are Dependent on Location. Mol Imaging Biol 19:215-224
Johnson, Rachelle W; Sowder, Miranda E; Giaccia, Amato J (2017) Hypoxia and Bone Metastatic Disease. Curr Osteoporos Rep 15:231-238
Chiou, Shin-Heng; Risca, Viviana I; Wang, Gordon X et al. (2017) BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer. Cancer Discov 7:1184-1199
Sun, Ramon C; Koong, Albert; Giaccia, Amato et al. (2016) Measuring the Impact of Microenvironmental Conditions on Mitochondrial Dehydrogenase Activity in Cultured Cells. Adv Exp Med Biol 899:113-20

Showing the most recent 10 out of 191 publications